Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
This is Enzene Biosciences third biosimilar to be approved
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Akums invested Rs. 272 crore in capital expenditure during FY25
Subscribe To Our Newsletter & Stay Updated
